Drugs & Targets FDA approves treatment for patients with HER2-positive breast cancer who have progressed on available therapies January 03, 2020Vol.46 No.01
Drugs & Targets FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer January 03, 2020Vol.46 No.01
Drugs & Targets FDA grants Avatrombopag Orphan Drug Designation for chemotherapy-induced thrombocytopenia January 03, 2020Vol.46 No.01
Drugs & Targets Karyopharm submits NDA for Xpovio for relapsed or refractory diffuse large B-cell lymphoma January 03, 2020Vol.46 No.01
Drugs & Targets Amgen and Allergan submit BLA for biosimilar candidate to Rituxan January 03, 2020Vol.46 No.01
Drugs & Targets China approves Zejula as maintenance therapy for recurrent ovarian cancer January 03, 2020Vol.46 No.01
Drugs & TargetsFree FDA issues draft guidance to foster pediatric oncology product development December 13, 2019Vol.45 No.46
Drugs & TargetsFree FDA approves Avsola for same indications as Remicade December 13, 2019Vol.45 No.46
Drugs & TargetsFree FDA grants Janssen’s BCMA CAR-T therapy JNJ-4528 Breakthrough Therapy Designation for multiple myeloma indication December 13, 2019Vol.45 No.46
Drugs & Targets FDA approves Tecentriq + chemo as initial treatment metastatic non-squamous NSCLC indication December 06, 2019Vol.45 No.45
